Sanofi Q2 Earnings: Double-Digit Sales Growth, Solid Business EPS, and Upgraded 2025 Guidance

Sanofi reported Q2 sales growth of 10.1% at CER and business EPS of €1.59, up 8.3%. Pharma launches increased sales by 39.8%, while Dupixent sales grew 21.1% to €3.8 billion. The company refined its 2025 sales guidance to high single-digit growth and confirmed a strong business EPS rebound. Sanofi also closed the Opella transaction, creating a global consumer healthcare leader.

Sanofi reported robust Q2 sales growth of 10.1% at a constant exchange rate (CER), with business earnings per share (EPS) increasing to €1.59, up 8.3% [2]. The company's pharma launches contributed significantly to the sales increase, growing by 39.8% to reach €0.9 billion. Dupixent sales surged 21.1% to €3.8 billion, driven by the launch of the drug for chronic obstructive pulmonary disease (COPD). Vaccines sales also showed growth, rising 10.3% to €1.2 billion. Research and development (R&D) expenses increased by 17.7% to €1.9 billion, while selling, general, and administrative expenses grew by 7.8% to €2.3 billion. Overall, business EPS improved to €1.59, up 8.3% at CER and 1.9% reported, while International Financial Reporting Standards (IFRS) EPS stood at €3.24 [2].

Sanofi's pipeline progress included three regulatory approvals and three phase 3 readouts, showcasing the company's commitment to innovation. The approvals included Dupixent BP (US), Sarclisa NDMM, TE (EU), and MenQuadfi meningitis (US), while the phase 3 readouts included itepekimab COPD (one met the primary endpoint/one did not) and positive SP0087 in rabies prevention. Additionally, the company received seven regulatory designations, including orphan and fast track, in rare diseases, neurology, and oncology [2].

Sanofi also closed the Opella transaction, creating a global consumer healthcare leader. This strategic move is expected to enhance the company's market position and drive further growth [2].

Sanofi's refined 2025 sales guidance now projects high single-digit growth, positioning the company for continued success in the coming years.

References:
[1] https://finance.yahoo.com/news/azn-q2-earnings-meet-estimates-131200203.html
[2] https://www.globenewswire.com/news-release/2025/07/31/3124660/0/en/Press-Release-Q2-double-digit-sales-and-solid-business-EPS-growth-2025-sales-guidance-is-now-high-single-digit-growth-at-upper-end-of-range.html